GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Debt-to-Revenue

PharmaRoth Labs (PharmaRoth Labs) Debt-to-Revenue : 0.00 (As of Mar. 2011)


View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaRoth Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's annualized Revenue for the quarter that ended in Mar. 2011 was $0.80 Mil. PharmaRoth Labs's annualized Debt-to-Revenue for the quarter that ended in Mar. 2011 was 0.00.


PharmaRoth Labs Debt-to-Revenue Historical Data

The historical data trend for PharmaRoth Labs's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Debt-to-Revenue Chart

PharmaRoth Labs Annual Data
Trend Jun08 Jun09 Jun10
Debt-to-Revenue
N/A N/A N/A

PharmaRoth Labs Quarterly Data
Mar07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A -

Competitive Comparison of PharmaRoth Labs's Debt-to-Revenue

For the Biotechnology subindustry, PharmaRoth Labs's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaRoth Labs's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaRoth Labs's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PharmaRoth Labs's Debt-to-Revenue falls into.



PharmaRoth Labs Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaRoth Labs's Debt-to-Revenue for the fiscal year that ended in Jun. 2010 is calculated as

PharmaRoth Labs's annualized Debt-to-Revenue for the quarter that ended in Mar. 2011 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2011) Revenue data.


PharmaRoth Labs Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaRoth Labs (PharmaRoth Labs) Business Description

Traded in Other Exchanges
N/A
Address
8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117
PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines